• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Met

  2026-05-12

  This study presents a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, advancing in vitro models for pharmacokinetic analysis. The resulting organoids exhibit mature epithelial differentiation and functional cytochrome P450 activities, providing a robust platform for evaluating CYP2C19 substrate metabolism in drug discovery.

• Degarelix Acetate: Workflow Optimization for Prostate Cancer

  2026-05-12

  Degarelix acetate, a potent GnRH receptor antagonist from APExBIO, empowers precise in vitro and in vivo hormone pathway interrogation. This guide translates cutting-edge aggregation science and validated workflows into clear, actionable protocols for hormone suppression and cancer research.

• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-05-11

  This article examines a recent study demonstrating that trelagliptin, a DPP-4 inhibitor, stimulates osteoblastic differentiation in MC3T3-E1 cells by increasing RUNX2 expression through an AMPK-dependent pathway. These findings suggest new therapeutic potential for osteoporosis and outline key workflow considerations for blood sample preparation in related research.

• Practical Guide: Calpain Inhibitor I, ALLN for Apoptosis & I

  2026-05-11

  Calpain Inhibitor I, ALLN (SKU A2602) offers targeted inhibition of calpain and cathepsin proteases, supporting standardized workflows in apoptosis and ischemia-reperfusion injury research. It is best suited for cell-based and in vivo models requiring potent, selective protease inhibition. Use is not recommended for diagnostic or medical applications.

• Nigericin Sodium Salt: Technical Guide for Ion Transport Stu

  2026-05-10

  Nigericin sodium salt enables researchers to manipulate potassium and hydrogen ion gradients across biological membranes, making it a key tool for investigating ion transport, cytoplasmic pH regulation, and platelet aggregation modulation. Its use is best suited to controlled in vitro workflows; it is not appropriate for diagnostic or clinical applications, and careful handling is essential due to solubility and stability characteristics.

• SIS3 Smad3 Inhibitor: Precision TGF-β Pathway Modulation in

  2026-05-09

  SIS3 (Smad3 inhibitor) empowers researchers with unparalleled specificity for targeting the TGF-β/Smad3 axis, driving breakthroughs in fibrosis, osteoarthritis, and renal pathology studies. Discover robust workflows, troubleshooting strategies, and the translational leap enabled by SIS3—trusted by APExBIO for consistent results.

• RNA Pol II Inhibition Triggers Regulated Apoptosis via PDAR

  2026-05-08

  Harper et al. (2025) demonstrate that cell death upon RNA polymerase II inhibition is not a passive result of mRNA decay, but a regulated apoptotic process signaled by the loss of hypophosphorylated RNA Pol IIA. This work redefines how transcriptional machinery perturbation initiates apoptosis, with broad implications for drug mechanism studies and apoptosis research.

• Filipin III: Strategic Advances in Membrane Cholesterol Dete

  2026-05-08

  This thought-leadership article explores the mechanistic and translational value of Filipin III—a polyene macrolide antibiotic and gold-standard cholesterol probe—for modern membrane biology. Integrating recent findings on cholesterol-driven pathology, protocol best practices, and the evolving competitive landscape, this analysis provides actionable guidance for translational researchers seeking to bridge high-resolution cholesterol detection with clinically relevant disease models.

• Reliable Apoptosis Detection: DAPI Solution (1 mg/mL) in Pra

  2026-05-07

  This article delivers scenario-driven guidance for using DAPI Solution (1 mg/mL) (SKU K2401) to overcome common cell viability and apoptosis detection challenges. Through real-world Q&A, it highlights evidence-based protocol optimization, vendor selection, and data interpretation for robust, reproducible nuclear visualization in biomedical research.

• Gastrin I (human): Driving Translational Insight in GI Resea

  2026-05-07

  This thought-leadership article explores how high-purity Gastrin I (human) empowers translational researchers to mechanistically dissect gastric acid secretion and bridge in vitro findings from hiPSC-derived organoid models to clinical innovation. We synthesize evidence from organoid pharmacokinetic studies, competitive landscape analyses, and hands-on workflow guidance—demonstrating why APExBIO’s peptide is a strategic choice for next-generation gastrointestinal disorder research.

• Puerarin Regulates Gut Microbiota and Thermogenesis in T2D M

  2026-05-06

  This study delineates how puerarin, a phytochemical from Pueraria lobata, mitigates glucose and lipid metabolic disorders in type 2 diabetes by rebalancing gut microbiota and enhancing adipose tissue thermogenesis. The findings highlight the mechanistic interplay between microbial metabolites, signaling pathways, and energy regulation, offering new avenues for diabetes intervention.

• CK2 Inhibition With CX-4945: Bridging Cancer and Virology

  2026-05-06

  This article explores the mechanistic rationale and translational strategies for targeting casein kinase 2 (CK2) with CX-4945 (Silmitasertib) in both oncology and antiviral research. By integrating recent virology findings—highlighting the CK2α–VP2 interaction exploited by chicken infectious anemia virus (CIAV)—with well-established cancer biology, we provide actionable guidance for researchers seeking to leverage CK2 inhibition across disease domains. Drawing on peer-reviewed evidence, workflow recommendations, and APExBIO’s leadership in CK2 inhibitor supply, the article distinguishes itself from typical product pages by offering cross-domain insight, practical protocol parameters, and a forward-looking perspective on the future of host-targeted therapeutics.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-05

  Wang et al. (2024) identify the METTL16-SENP3-LTF signaling axis as a central mechanism underlying ferroptosis resistance and tumor progression in hepatocellular carcinoma (HCC). Their integrative analyses reveal how RNA m6A modification and iron metabolism converge to promote HCC, highlighting new molecular targets for sensitizing tumors to ferroptosis-based therapies.

• 2X Taq PCR Master Mix (with dye): Optimizing PCR Fidelity fo

  2026-05-05

  Explore how the 2X Taq PCR Master Mix (with dye) elevates molecular biology PCR workflows, with a unique focus on infectious disease ecology and assay design. Discover advanced insights and practical parameters for researchers.

• Modeling Breast Tumor Relapse: Proliferation Tracing in Mice

  2026-05-04

  This study introduces a dual recombinase genetic system in the PyMT mouse model to trace and ablate proliferating breast cancer cells, enabling robust modeling of tumor relapse. Single-cell transcriptomic analysis reveals microenvironmental changes and persistence of therapy-resistant subpopulations, offering a valuable resource for preclinical testing of relapse-targeted therapies.

619 records 8/42 page Previous Next First page 上5页 678910 下5页 Last page